title: Treatment of iris melanoma and secondary neovascular glaucoma using bevacizumab and plaque radiotherapy.
authors.forename: Carlos
authors.initials: C
authors.lastname: Bianciotto
authors.forename: Carol L
authors.initials: CL
authors.lastname: Shields
authors.forename: Brian
authors.initials: B
authors.lastname: Kang
authors.forename: Jerry A
authors.initials: JA
authors.lastname: Shields
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001918:Brachytherapy; D003131:Combined Modality Therapy; D015355:Glaucoma, Neovascular / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006068:Gonioscopy; D006801:Humans; D007429:Intraocular Pressure; D015811:Iris Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008875:Middle Aged; D014463:Ultrasonography; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab